Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacks

Roche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage.

The comment accompanied an announcement that Roche will reduce its development pipeline, concentrating resources on the most promising candidates.

Schinecker contrasted Roche's outlook with recent late-stage failures reported by other European drugmakers such as Novartis, Novo Nordisk and AstraZeneca.

The strategy signals a shift toward projects with higher chances of approval, which could bolster the company's long-term growth prospects.